CytomX Therapeutics, Inc. (CTMX) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $23.09, up from yesterday’s close by 21.53%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
This company has been competing with others in the Healthcare space and offers its own combination of interesting factors CytomX Therapeutics, Inc. (CTMX) currently trades with a market capitalization of $846.48 Million.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For CTMX, the company currently has $272.86 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $139.12 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $-0.14 on a per share basis this quarter. Perhaps, that suggests something about why 78.84% of the outstanding share supply is held by institutional investors.
Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, CytomX Therapeutics, Inc. recorded a 52-week high of $20.02. It is now trading -3.07% off that level. The stock is trading $16.01 its 50-day moving average by -7.08%. The stock carved out a 52-week low down at $9.85.
In recent action, CytomX Therapeutics, Inc. (CTMX) has made a move of +37.69% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.36, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.58% with $33.94 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of CTMX.